Incyte has reported that its Phase III TRuE-AD3 study of ruxolitinib cream (Opzelura) for the treatment of atopic dermatitis (AD) in children has met its primary endpoint.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,